Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Further Reading

Southampton researchers find new approach to reverse treatment resistance in lymphoma patients

Southampton researchers find new approach to reverse treatment resistance in lymphoma patients

Novel therapy decreases incidence of bleeding by 87% in hemophilia A patients with inhibitors

Novel therapy decreases incidence of bleeding by 87% in hemophilia A patients with inhibitors

Scientists develop novel DNA-based strategy to protect against broad array of influenza viruses

Scientists develop novel DNA-based strategy to protect against broad array of influenza viruses

New monoclonal antibody shows efficacy in chronic migraine patients with medication overuse

New monoclonal antibody shows efficacy in chronic migraine patients with medication overuse

Research details how lymphoma cells acquire resistance to targeted therapy

Research details how lymphoma cells acquire resistance to targeted therapy

Antibody-based theranostic agent shows promise for identifying and treating pancreatic tumors

Antibody-based theranostic agent shows promise for identifying and treating pancreatic tumors

Novartis announces data revealing efficacy of new monoclonal antibody therapy in preventing migraine

Novartis announces data revealing efficacy of new monoclonal antibody therapy in preventing migraine

Combination therapy has complete response rate in children, young adults with Hodgkin lymphoma

Combination therapy has complete response rate in children, young adults with Hodgkin lymphoma

Novartis, Bristol-Myers Squibb collaborate to examine combination therapies for metastatic colorectal cancer

Novartis, Bristol-Myers Squibb collaborate to examine combination therapies for metastatic colorectal cancer

Trial shows promising results for new medicine in treating severe asthma patients

Trial shows promising results for new medicine in treating severe asthma patients

Investigational biologic may reduce need for systemic corticosteroids in patients with severe asthma

Investigational biologic may reduce need for systemic corticosteroids in patients with severe asthma

New findings could lead to first broadly effective ebolavirus therapies and vaccines

New findings could lead to first broadly effective ebolavirus therapies and vaccines

Composition, function of intestinal bacteria could predict response to biologic drugs in IBD patients

Composition, function of intestinal bacteria could predict response to biologic drugs in IBD patients

Breakthrough therapy reduces symptoms of Graves' eye disease in clinical trials

Breakthrough therapy reduces symptoms of Graves' eye disease in clinical trials

Latest advances in antibody delivery mediated by rAAV for treatment of chronic and infectious diseases

Latest advances in antibody delivery mediated by rAAV for treatment of chronic and infectious diseases

Patients with inducible urticaria can benefit from treatment with asthma drug

Patients with inducible urticaria can benefit from treatment with asthma drug

Antibody treatment protects non-human primates against deadly Marburg and Ravn viruses

Antibody treatment protects non-human primates against deadly Marburg and Ravn viruses

Experimental treatment cures Marburg and Ravn virus infection in animals

Experimental treatment cures Marburg and Ravn virus infection in animals

Researchers track in real-time how melanoma cells move to form tumors

Researchers track in real-time how melanoma cells move to form tumors

Amgen, UCB present romosozumab Phase 2 results at ENDO 2017

Amgen, UCB present romosozumab Phase 2 results at ENDO 2017